NB004 / Newbay Pharma, Roche - LARVOL DELTA

Preclinical antitumor activity and first-in-human phase I study of NB004/GDC-0570, a novel pan-PIM kinase inhibitor, in patients with advanced solid tumors (AACR 2024) - P1 | "Remarkably, in NSCLC PDX models with acquired resistance to KRASis, strong combination efficacy was observed between NB004 and sotorasib, resulting in complete tumor regression. These results warrant further evaluation of this drug in combination with other therapeutic agents. The combination part of the trial is currently open for enrollment (NCT05036291)."

First-in-human • Metastases • P1 data • Preclinical • Hematological Malignancies • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • KRAS • PIM1

Case Report: Complete remission in a neonate with high-risk neuroblastoma harboring MYCN amplification and 1p deletion: a case for aggressive early intervention, and literature review. (PubMed, Front Pediatr) - "To the best of our knowledge, this is the first reported case of neonatal neuroblastoma with concurrent MYCN amplification and 1p deletion achieving favorable outcome through comprehensive multimodal therapy. This case underscores the importance of early diagnosis, genetic profiling, and aggressive treatment in managing high-risk neuroblastoma in neonates."

Journal • Bone Marrow Transplantation • Infectious Disease • Neuroblastoma • Oncology • Pediatrics • Septic Shock • Solid Tumor • Transplantation • MYCN

Sensitive liquid biopsy monitoring correlates with outcome in the prospective international GPOH-DCOG high-risk neuroblastoma RT-qPCR validation study. (PubMed, J Exp Clin Cancer Res) - "This study validates the association of not clearing of BM metastases by sensitive RT-qPCR detection with very poor outcome. We therefore propose implementation of RT-qPCR for minimal residual disease testing in neuroblastoma to guide therapy."

Biomarker • Journal • Liquid biopsy • CNS Tumor • Neuroblastoma • Oncology • Pediatrics • Solid Tumor • HOXB6 • PHOX2B

Lead Optimization Yielding a pan-Pim Inhibitor GDC-0570/NB004 for Cancer Treatment in the Clinical Testing (ACS-Sp 2024) - "The structure of GDC-0570 has not been disclosed. Currently, GDC-0570 is in active Phase 1 clinical trial."

Clinical • Hematological Malignancies • Multiple Myeloma • Oncology

Discovery of GDC-0570/NB004 as a second-generation pan-Pim inhibitor through extensive optimization for cancer treatment (ACS-Fall 2023) - "This is the first time that the structure of GDC-0570 will be fully disclosed. Currently, GDC-0570 is in active phase 1 clinical trial."

Hematological Malignancies • Multiple Myeloma • Oncology

Newly added product (Businesswire) - Preclinical, Oncology, MM, Prostate Cancer

Pipeline update